Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Oh
S J
SJ
Department of Neurology, University of Alabama at Birmingham 35294, USA.
Kim
D S
DS
Kwon
K H
KH
Tseng
A
A
Mussell
H
H
Claussen
G C
GC
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000077770:Amifampridine; D018288:Carcinoma, Small Cell / Q000150:complications / Q000628:therapy; D005260:Female; D019791:Guanidine / Q000627:therapeutic use*; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008175:Lung Neoplasms / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010277:Parasympathomimetics / Q000627:therapeutic use*; D026902:Potassium Channel Blockers; D011729:Pyridostigmine Bromide / Q000627:therapeutic use*; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000150:complications / Q000628:therapy
D010277:Parasympathomimetics; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine; D019791:Guanidine; D011729:Pyridostigmine Bromide; D000077770:Amifampridine